Novo Nordisk
Assessment date: Mar 2017
Considering its size and market dominance in the control of diabetes, especially in the US, Novo Nordisk faces a broader range of issues, and is exposed to more risk than its peers by our analysis. President Trump is already accusing pharmaceutical firms of exploitation in the US market, Novo Nordisk faces lawsuits for price fixing, and its main product, insulin, is losing reputation as a cure for diabetes. Novo Nordisk has responded decisively in replacing its CEO and leadership in the US and is moving its thought-leadership articles away from insulin, despite this still being its primary product. Novo Nordisk’s reporting maturity, while high, will have to improve further in order to weather the storm to come.
See the executive summary for a more complete overview of FarSight’s analysis for Novo Nordisk. Buy our full report for detailed analysis and supporting discussion.
